Aminothiadiazole (NSC 4728) in Patients with Advanced Carcinoma of the Endometrium
- 1 February 1990
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 13 (1) , 39-41
- https://doi.org/10.1097/00000421-199002000-00011
Abstract
Twenty-one evaluable patients with advanced carcinoma of the endometrium were treated with aminothiadiazole at a dosage of 125 mg/m2 weekly. Twelve had received prior chemotherapy. Seven patients had stable disease; 14 had increasing disease. There were two life-threatening toxic episodes. Aminothiadiazole used in this dosage and schedule has negligible activity in previously treated patients with carcinoma of the endometrium.This publication has 6 references indexed in Scilit:
- Aminothiadiazole (NSC 4728) in Patients with Advanced Nonsquamous Carcinoma of the CervixAmerican Journal of Clinical Oncology, 1989
- Aminothiadiazole (NSC #4728) in Patients With Advanced Cervical Carcinoma A Phase II Study of the Gynecologic Oncology GroupAmerican Journal of Clinical Oncology, 1987
- Aminothiadiazole (NSC 4728) in Patients with Advanced Ovarian Carcinoma A Phase II Study of the Gynecologic Oncology GroupAmerican Journal of Clinical Oncology, 1986
- MECHANISM OF ACTION OF 2-AMINO-1,3,4-THIADIAZOLE (NSC 4728)1977
- THE ANTILEUKEMIC ACTION OF 2 THIADIAZOLE DERIVATIVES1960
- STUDIES OF THE URICOGENIC EFFECT OF 2-SUBSTITUTED THIADIAZOLES IN MAN*Journal of Clinical Investigation, 1959